This study is in progress, not accepting new patients
Safety and Dose-Finding Study of DTX301 (scAAV8OTC) in Adults With Late-Onset OTC Deficiency
Summary
- Eligibility
- for people ages 18 years and up (full criteria)
- Location
- at San Francisco, California and other locations
- Dates
- study startedestimated completion
- Principal Investigator
- by Renata Gallagher
Description
Summary
Official Title
Details
Keywords
Eligibility
Locations
Lead Scientist at UCSF
- Renata Gallagher
Professor, Pediatrics. Authored (or co-authored) 54 research publications.
Details
- Status
- in progress, not accepting new patients
- Start Date
- Completion Date
- (estimated)
- Sponsor
- Ultragenyx Pharmaceutical Inc
- ID
- NCT02991144
- Phase
- Phase 1/2
- Study Type
- Interventional
- Last Updated